SAN FRANCISCO, Jan 16 (Reuters) - The pharmaceutical industry ... they are approved for different indications. For instance, Novo Nordisk's (NOVOb.CO), opens new tab diabetes treatment Ozempic ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

With sales of Novo Nordisk’s obesity blockbuster Wegovy ... Nevertheless, the Danish pharma continues to recognize the importance of its production network, with the company noting in its ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as it boosts production of ...

Dual agonists are proving to be especially promising candidates, and many pharmaceutical companies have created some versions. Novo Nordisk recently reported data from a phase 1b/2a clinical trial ...

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its popular diabetes and weight loss medicines, including Wegovy and ...

Novo Nordisk and Eli Lilly have asked the federal government to list their blockbuster weight-loss drugs on the Pharmaceutical Benefits Scheme, arguing funding the treatment will reduce a costly ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.

Monlunabant, formerly INV-202, came from Novo Nordisk’s 2023 acquisition of Inversago Pharma. The Canadian company designed this small molecule to preferentially target CB1 receptors in the ...

Speaking at the reopening of the Thailand office of Novo Nordisk, a leading global healthcare company, Mr Annan highlighted how the company is driven not only by pharmaceutical excellence but also ...